View Older Stories

Nov 26, 2025 07:48AM H.C. Wainwright Reiterates Buy Rating on Plus Therapeutics Inc. (PSTV)

Nov 24, 2025 07:31AM Plus Therapeutics completes FDA meeting on REYOBIQ cancer treatment

Nov 20, 2025 07:30AM Plus Therapeutics secures Humana coverage for brain cancer test

Nov 17, 2025 07:31AM Plus Therapeutics gets 180-day extension for NASDAQ compliance

Nov 3, 2025 06:46AM Plus Therapeutics Inc. (PSTV) PT Lowered to $2 at H.C. Wainwright

Oct 30, 2025 05:54PM Plus Therapeutics (PSTV) Misses Q3 EPS by 4c

Oct 21, 2025 07:31AM Plus Therapeutics promotes executives, expands CNSide diagnostic operations

Sep 25, 2025 07:30AM Plus Therapeutics secures UnitedHealthcare coverage for brain cancer test

Sep 22, 2025 07:30AM Plus Therapeutics receives $1.9 million CPRIT advance payment

Sep 18, 2025 07:31AM Plus Therapeutics subsidiary receives clinical lab accreditation

Sep 3, 2025 07:02AM D. Boral Capital Upgrades Plus Therapeutics Inc. (PSTV) to Buy

Aug 26, 2025 07:31AM Plus Therapeutics regains compliance with NASDAQ listing criteria

Aug 15, 2025 01:42PM Plus Therapeutics Inc. (PSTV) PT Lowered to $3 at Maxim Group

Aug 15, 2025 07:30AM Plus Therapeutics meets Nasdaq equity requirement with $3 million

Aug 14, 2025 05:24PM Plus Therapeutics (PSTV) Misses Q2 EPS by 1c

Aug 14, 2025 07:32AM Plus Therapeutics presents CNSide assay data at CNS conference

Aug 12, 2025 04:09PM Plus Therapeutics (PSTV) Files for 33M Share Offering by Selling Stockholders

Jul 31, 2025 07:32AM Plus Therapeutics launches CNSide diagnostic in Texas

Jul 23, 2025 07:30AM Plus Therapeutics receives $1.6 million advance from Texas cancer institute

Jul 15, 2025 07:31AM Plus Therapeutics to present REYOBIQ trial results at CNS conference

Jul 8, 2025 07:31AM Plus Therapeutics (PSTV) begins treating patients in REYOBIQ dose optimization trial

Jun 30, 2025 07:30AM Plus Therapeutics (PSTV) Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ

Jun 27, 2025 06:49AM Plus Therapeutics Inc. (PSTV) PT Lowered to $3 at H.C. Wainwright

Jun 26, 2025 07:31AM Plus Therapeutics (PSTV) Provides Business Update on CNSide Diagnostics Subsidiary

Jun 25, 2025 07:30AM Plus Therapeutics (PSTV) Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM

Jun 24, 2025 07:32AM Plus Therapeutics (PSTV) Announces Comprehensive Restructuring of $15M March 2025 Equity Financing

Jun 20, 2025 06:17AM Plus Therapeutics (PSTV) Files for 17M Share Offering by Selling Stockholders

Jun 18, 2025 06:04AM Plus Therapeutics (PSTV) Files for 17M Share Offering by Selling Stockholders

Jun 5, 2025 06:23AM Plus Therapeutics Inc. (PSTV) PT Raised to $20.50 at Ascendiant Capital

May 23, 2025 04:27PM Plus Therapeutics (PSTV) receives notice from Nasdaq regarding late 10-Q

May 14, 2025 07:31AM Plus Therapeutics (PSTV) Says REYOBIQ Showed Clinical Benefit and Safety in the ReSPECT-LM Trial

Apr 23, 2025 08:02AM Plus Therapeutics (PSTV) Appoints Kyle Guse to its Board

Apr 15, 2025 07:30AM Plus Therapeutics (PSTV) Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Apr 4, 2025 04:39PM Plus Therapeutics (PSTV) Files for 1.57B Share Offering by Selling Stockholders

Mar 28, 2025 06:41AM Plus Therapeutics Inc. (PSTV) PT Lowered to $5.50 at H.C. Wainwright

Mar 20, 2025 07:30AM Plus Therapeutics (PSTV) Introduces REYOBIQ, FDA-Accepted Proprietary Name for Lead Drug Candidate

Mar 17, 2025 07:02AM D. Boral Capital Starts Plus Therapeutics Inc. (PSTV) at Buy, PT $9

Mar 11, 2025 11:00AM D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Mar 10, 2025 07:30AM Plus Therapeutics (PSTV) Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Mar 7, 2025 07:30AM Plus Therapeutics (PSTV) Announces Publication Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Mar 6, 2025 07:32AM Plus Therapeutics (PSTV) Granted FDA Orphan Drug Designation for Rhenium Obisbemeda

Mar 4, 2025 02:13PM Plus Therapeutics (PSTV) Announces $15M Private Placement

Feb 26, 2025 07:30AM Plus Therapeutics (PSTV) Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Feb 24, 2025 07:31AM Plus Therapeutics (PSTV) Announces Leadership Appointments for CNSide Diagnostics Subsidiary

Feb 20, 2025 07:30AM Plus Therapeutics (PSTV) Appoints Michael Rosol as Chief Development Officer

Feb 18, 2025 07:30AM Plus Therapeutics (PSTV) Secures $5.7M Financing to Support Leptomeningeal Metastases Program

Dec 17, 2024 07:30AM Plus Therapeutics (PSTV) Presents Positive ReSPECT-LM Phase 1 Interim Data

Dec 3, 2024 07:31AM Plus Therapeutics (PSTV) Expands Strategic Agreement with Telix IsoTherapeutics

Nov 26, 2024 07:07AM H.C. Wainwright Reiterates Buy Rating on Plus Therapeutics Inc. (PSTV)

Nov 25, 2024 07:31AM Plus Therapeutics (PSTV) Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases

View Older Stories